Sample Collection for Ongoing Research and Product Evaluation Study

Part of paid clinical trials in Austin, Texas.

Sponsor
Natera, Inc.
Study ID
NCT07318051
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors. The collected specimens and information will be used to evaluate the clinical performance of Natera's molecular residual disease (MRD) testing across multiple cancer types. The study aims to assess the ability of Natera's assays to detect circulating tumor DNA (ctDNA) as a marker for disease recurrence and treatment response.

Key Dates

Start date
Jul 21, 2025
Status verified
Dec 2025
Primary completion
Jan 31, 2035
Completion
Jan 31, 2035

Study Design

Enrollment
9,600 participants (estimated)

Primary Outcome Measure

Primary Outcome - Collection of Blood and Residual Tissue Specimens for Cancer Assay Development [ Time Frame: 8 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Natera, Inc.AustinTexas78753
Jamie McKenzie, MD
[email protected]
650-489-9050

Find similar trials in Austin, TX

By condition
Breast cancerHead and neck cancerLiver cancerLung cancerMelanomaOvarian cancerPancreatic cancerProstate cancerColorectal cancerEndometrial cancer
By specialty
OncologyBreast oncologyWomen's healthENTGI oncologyHepatologyLung oncologyLung diseaseSkin cancerDermatologyGynecologic oncologyProstate oncologyMen's healthUrology
By research site
Natera, Inc.· Austin, TX

Related Studies